

Montegress

Montelukast 4 mg / 5 mg Mouth Dissolving Tablets & 10 mg Tablets

<u>la Renon®</u>



Montelukast 4 mg / 5 mg Mouth Dissolving Tablets & 10 mg Tablets

Description:

Montelukast sodium, the active ingredient in MONTEGRESS, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor

Indications And Usage:

- Asthma
- Exercise-Induced Bronchoconstriction (EIB)
- Allergic Rhinitis

Mechanism of Action:

The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, -adrenergic receptor). Montelukast inhibits physiologic actions of LTD4 at the CysLT1β cholinergic, or receptor without any agonist activity.

Dosage And Administration:

Asthma and Allergic Rhinitis:

MONTEGRESS should be taken once daily in the evening. The following doses are recommended:

- For adults and adolescents 15 years of age and older: One 10-mg tablet.
- For pediatric patients 6 to 14 years of age: one 5-mg MD tablet.
- For pediatric patients 2 to 5 years of age: one 4-mg MD tablet.

Exercise-Induced Bronchoconstriction (EIB) For prevention of EIB, a single dose of MONTEGRESS should be taken at least 2 hours before exercise. The following doses are recommended:

- For adults and adolescents 15 years of age and older: one 10-mg tablet.
- For pediatric patients 6 to 14 years of age: one 5-mg MD tablet. An additional dose of MONTEGRESS should not be taken within 24 hours of a previous dose.

Daily administration of MONTEGRESS for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

Dosage Forms And Strengths:

MONTEGRESS 10 mg is white, rounded shaped Film-Coated tablets.

MONTEGRESS 5 mg is white, round, bi-convex-shaped mouth dissolving Tablets.

MONTEGRESS 4 mg is white, oval, bi-convex-shaped mouth dissolving Tablets.

la	Renon®

La Renon Healthcare

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone: + 91-79-3046-1000 (30 lines) Fax: +91-79-3046-1001 E-mail: info@larenon.com Web: www.larenon.com

I am
Call me on
Mail me at